Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.
intracellular adhesion molecule-1
nivolumab
non-small cell lung cancer
programmed cell-death protein-1
vascular cell adhesion molecule-1
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
01
08
2021
received:
12
04
2021
accepted:
08
08
2021
pubmed:
15
8
2021
medline:
18
3
2022
entrez:
14
8
2021
Statut:
ppublish
Résumé
High circulating levels of cellular adhesion molecules (CAMs) in non-small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre-treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC. Seventy one patients with advanced NSCLC, treated with nivolumab at the dose of 3 mg/kg every 14 days, were enrolled. Maximum follow-up time was 3 years. Serum levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intracellular Adhesion Molecule-1 (ICAM-1) were measured at baseline and before each nivolumab administration. Endpoints of the study were a composite outcome of survival ≥2 years or absence of disease progression at the end of the follow-up, and the overall survival. Composite outcome and overall survival were positively associated with VCAM-1 baseline levels and with the reduction of VCAM-1 during the treatment. After adjustment for potential confounders, the change in VCAM-1 serum levels during the treatment was an independent predictor of overall survival. High baseline serum levels of VCAM-1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
High circulating levels of cellular adhesion molecules (CAMs) in non-small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre-treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC.
MATERIALS AND METHODS
METHODS
Seventy one patients with advanced NSCLC, treated with nivolumab at the dose of 3 mg/kg every 14 days, were enrolled. Maximum follow-up time was 3 years. Serum levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intracellular Adhesion Molecule-1 (ICAM-1) were measured at baseline and before each nivolumab administration. Endpoints of the study were a composite outcome of survival ≥2 years or absence of disease progression at the end of the follow-up, and the overall survival.
RESULTS
RESULTS
Composite outcome and overall survival were positively associated with VCAM-1 baseline levels and with the reduction of VCAM-1 during the treatment. After adjustment for potential confounders, the change in VCAM-1 serum levels during the treatment was an independent predictor of overall survival.
CONCLUSIONS
CONCLUSIONS
High baseline serum levels of VCAM-1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy.
Identifiants
pubmed: 34390488
doi: 10.1111/eci.13668
pmc: PMC9286788
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Vascular Cell Adhesion Molecule-1
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13668Subventions
Organisme : Fondazione Cassa di Risparmio di Genova e Imperia
Organisme : Ministero della Salute
ID : 2754291
Informations de copyright
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Int J Cardiol. 2017 Mar 15;231:1-5
pubmed: 27989579
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Br J Pharmacol. 2017 Nov;174(21):3713-3726
pubmed: 28127745
Eur J Clin Invest. 2021 May;51(5):e13467
pubmed: 33259635
Clin Exp Metastasis. 2019 Oct;36(5):449-456
pubmed: 31376097
Biomed Pharmacother. 2019 Sep;117:109199
pubmed: 31387181
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Eur J Clin Invest. 2022 Jan;52(1):e13668
pubmed: 34390488
Biomed Pharmacother. 2020 Jul;127:109996
pubmed: 32388240
Int J Mol Sci. 2018 Apr 02;19(4):
pubmed: 29614819
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Virchows Arch. 1996 Apr;428(1):21-7
pubmed: 8646365
Clin Cancer Res. 2008 Mar 1;14(5):1407-12
pubmed: 18316562
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287347
Oncologist. 2018 Aug;23(8):936-942
pubmed: 29567824
ESMO Open. 2020 Sep;5(Suppl 1):e000597
pubmed: 32933940
Int J Mol Sci. 2017 Mar 06;18(3):
pubmed: 28272300
Clin Transl Oncol. 2020 Sep;22(9):1603-1610
pubmed: 32048158
Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358
pubmed: 31327024
Cancer. 2020 Jan 15;126(2):260-270
pubmed: 31691957
Clin Lung Cancer. 2018 Mar;19(2):120-129
pubmed: 29153898